Oncodesign Precision Medicine (ALOPM.PA) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ALOPM.PA · Stock Price

EUR 0.45+0.08 (+22.70%)

Market Cap: $10.3M

Historical price data

Market Cap: $10.3MPipeline: 1 drugFounded: 1995HQ: Dijon, France

Sector Ranking#348 in Small Molecule Drugs #40 in AI / Machine Learning

Overview

Oncodesign Precision Medicine is a publicly traded French biotech focused on developing precision therapies for resistant cancers and neurodegenerative diseases. Its strategy is built on a proprietary drug discovery engine, Nanocyclix®, which generates highly selective macrocyclic kinase inhibitors, and an AI-driven target identification platform, OncoSNIPER. Key achievements include advancing two clinical-stage assets, OPM-101 (RIPK2 inhibitor for oncology/IBD) and OPM-201 (LRRK2 inhibitor for Parkinson's), with the latter receiving support from The Michael J. Fox Foundation.

OncologyNeurodegenerative DiseasesInflammatory Bowel Disease

Technology Platform

Proprietary Nanocyclix® platform for discovering small macrocyclic kinase inhibitors, complemented by the OncoSNIPER AI platform for target identification and the PROMETHE® collaborative ecosystem.

Pipeline

1

1 drug in pipeline

Drug	Indication	Stage	Watch
OPM-101	Advanced Melanoma	Phase 1/2

Funding History

1

Total raised:$10.5M

IPO$10.5MUndisclosedJul 9, 2014

Opportunities

OPM has near-term catalysts with Phase 1b/2 trials for both lead assets starting in 2026.

The LRRK2 program, backed by MJFF, offers an orphan drug pathway in Parkinson's, while the RIPK2 inhibitor addresses massive unmet needs in immuno-oncology resistance and IBD.

Successful clinical data could drive significant partnership or M&A interest.

Risk Factors

The company faces severe financial risk as a pre-revenue micro-cap needing to fund two costly clinical trials.

High clinical failure risk is inherent in novel mechanisms, and OPM-201 faces strong competition from more advanced LRRK2 inhibitors.

Execution risk in managing parallel programs in different therapeutic areas is elevated.

Competitive Landscape

In LRRK2, OPM-201 is a close follower to Denali/Biogen and Neuron23's Phase 2 candidates, differentiating via a genetic subpopulation strategy. In RIPK2, OPM-101 holds a potential first-in-class lead in clinical development. The core Nanocyclix® platform competes with other kinase discovery technologies from larger firms.